共 487 条
[1]
Adamo V.(2008)Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data Journal of Clinical Oncology 26 15036-15036
[2]
Franchina T.(2008)Wild-type k-ras is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626-1634
[3]
Adamo B.(1998)Kirsten ras mutations in patients with colorectal cancer: the multicenter ‘RASCAL’ study J Natl Cancer Inst 90 675-684
[4]
Briguglio R.(2008)K-ras status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience (abstract) J Clin Oncol 26 18s-267
[5]
Restuccia E.(2008)The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer Pharmacogenomics J 8 256-2091
[6]
Chiofalo G.(2004)XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 2084-1615
[7]
Ferraro G.(2003)Methlenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy Clin Cancer Res 9 1611-4875
[8]
Caccamo D.(2005)Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'italia Meridonale J Clin Oncol 23 4866-2947
[9]
Ientile R.(2000)Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938-515
[10]
Amado RG(2008)KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508-1750